Sickle Cell Disease Treatment Approaches

Jan 03, 2025

In September 2024, Pfizer voluntarily withdrew all lots of OXBRYTA for the treatment of SCD in all markets where it was approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanding access programs worldwide. The decision is based on the totality of clinical data, which now indicates tha...

Dec 27, 2024

Sickle cell disease is a hereditary blood disorder marked by abnormal hemoglobin, which leads to the deformation of red blood cells into a sickle shape. It is a major global health issue, especially common in individuals of African, Middle Eastern, Mediterranean, and South Asian descent. Based on DelveInsight's ...

Nov 27, 2019

Sickle cell disease is a haematological, genetic disorder that affects millions of people worldwide. According to the NIH, “Sickle cell disease is the most common inherited blood disorder in the United States, affecting 70,000 to 80,000 Americans’’. The estimates are somewhat similar to that of CDC’s according t...